Cargando…
Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants
Differences in innate immune ‘imprinting’ between vaccine adjuvants may mediate dissimilar effects on the quantity/quality of persisting adaptive responses. We compared antibody avidity maturation, antibody/memory B cell/CD4(+) T cell response durability, and recall responses to non-adjuvanted fract...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140094/ https://www.ncbi.nlm.nih.gov/pubmed/34021167 http://dx.doi.org/10.1038/s41541-021-00337-0 |
_version_ | 1783696120058216448 |
---|---|
author | Budroni, Sonia Buricchi, Francesca Cavallone, Andrea Bourguignon, Patricia Caubet, Magalie Dewar, Vincent D’Oro, Ugo Finco, Oretta Garçon, Nathalie El Idrissi, Mohamed Janssens, Michel Leroux-Roels, Geert Marchant, Arnaud Schwarz, Tino Van Damme, Pierre Volpini, Gianfranco van der Most, Robbert Didierlaurent, Arnaud M. Burny, Wivine |
author_facet | Budroni, Sonia Buricchi, Francesca Cavallone, Andrea Bourguignon, Patricia Caubet, Magalie Dewar, Vincent D’Oro, Ugo Finco, Oretta Garçon, Nathalie El Idrissi, Mohamed Janssens, Michel Leroux-Roels, Geert Marchant, Arnaud Schwarz, Tino Van Damme, Pierre Volpini, Gianfranco van der Most, Robbert Didierlaurent, Arnaud M. Burny, Wivine |
author_sort | Budroni, Sonia |
collection | PubMed |
description | Differences in innate immune ‘imprinting’ between vaccine adjuvants may mediate dissimilar effects on the quantity/quality of persisting adaptive responses. We compared antibody avidity maturation, antibody/memory B cell/CD4(+) T cell response durability, and recall responses to non-adjuvanted fractional-dose antigen administered 1-year post-immunization (Day [D]360), between hepatitis B vaccines containing Adjuvant System (AS)01(B), AS01(E), AS03, AS04, or Alum (NCT00805389). Both the antibody and B cell levels ranked similarly (AS01(B/E)/AS03 > AS04 > Alum) at peak response, at D360, and following their increases post-antigen recall (D390). Proportions of high-avidity antibodies increased post-dose 2 across all groups and persisted at D360, but avidity maturation appeared to be more strongly promoted by AS vs. Alum. Post-antigen recall, frequencies of subjects with high-avidity antibodies increased only markedly in the AS groups. Among the AS, total antibody responses were lowest for AS04. However, proportions of high-avidity antibodies were similar between groups, suggesting that MPL in AS04 contributes to avidity maturation. Specific combinations of immunoenhancers in the AS, regardless of their individual nature, increase antibody persistence and avidity maturation. |
format | Online Article Text |
id | pubmed-8140094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81400942021-06-03 Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants Budroni, Sonia Buricchi, Francesca Cavallone, Andrea Bourguignon, Patricia Caubet, Magalie Dewar, Vincent D’Oro, Ugo Finco, Oretta Garçon, Nathalie El Idrissi, Mohamed Janssens, Michel Leroux-Roels, Geert Marchant, Arnaud Schwarz, Tino Van Damme, Pierre Volpini, Gianfranco van der Most, Robbert Didierlaurent, Arnaud M. Burny, Wivine NPJ Vaccines Article Differences in innate immune ‘imprinting’ between vaccine adjuvants may mediate dissimilar effects on the quantity/quality of persisting adaptive responses. We compared antibody avidity maturation, antibody/memory B cell/CD4(+) T cell response durability, and recall responses to non-adjuvanted fractional-dose antigen administered 1-year post-immunization (Day [D]360), between hepatitis B vaccines containing Adjuvant System (AS)01(B), AS01(E), AS03, AS04, or Alum (NCT00805389). Both the antibody and B cell levels ranked similarly (AS01(B/E)/AS03 > AS04 > Alum) at peak response, at D360, and following their increases post-antigen recall (D390). Proportions of high-avidity antibodies increased post-dose 2 across all groups and persisted at D360, but avidity maturation appeared to be more strongly promoted by AS vs. Alum. Post-antigen recall, frequencies of subjects with high-avidity antibodies increased only markedly in the AS groups. Among the AS, total antibody responses were lowest for AS04. However, proportions of high-avidity antibodies were similar between groups, suggesting that MPL in AS04 contributes to avidity maturation. Specific combinations of immunoenhancers in the AS, regardless of their individual nature, increase antibody persistence and avidity maturation. Nature Publishing Group UK 2021-05-21 /pmc/articles/PMC8140094/ /pubmed/34021167 http://dx.doi.org/10.1038/s41541-021-00337-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Budroni, Sonia Buricchi, Francesca Cavallone, Andrea Bourguignon, Patricia Caubet, Magalie Dewar, Vincent D’Oro, Ugo Finco, Oretta Garçon, Nathalie El Idrissi, Mohamed Janssens, Michel Leroux-Roels, Geert Marchant, Arnaud Schwarz, Tino Van Damme, Pierre Volpini, Gianfranco van der Most, Robbert Didierlaurent, Arnaud M. Burny, Wivine Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants |
title | Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants |
title_full | Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants |
title_fullStr | Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants |
title_full_unstemmed | Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants |
title_short | Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants |
title_sort | antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140094/ https://www.ncbi.nlm.nih.gov/pubmed/34021167 http://dx.doi.org/10.1038/s41541-021-00337-0 |
work_keys_str_mv | AT budronisonia antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT buricchifrancesca antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT cavalloneandrea antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT bourguignonpatricia antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT caubetmagalie antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT dewarvincent antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT dorougo antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT fincooretta antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT garconnathalie antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT elidrissimohamed antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT janssensmichel antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT lerouxroelsgeert antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT marchantarnaud antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT schwarztino antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT vandammepierre antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT volpinigianfranco antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT vandermostrobbert antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT didierlaurentarnaudm antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT burnywivine antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants |